Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | MMP12 | P39900 | 2/20 | 0.33 |
| ▸ | MMP13 | P45452 | 2/20 | 0.33 |
| ▸ | MMP14 | P50281 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP16 | P51512 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30446463 | 0.87 | MYC (0.47) | MYCTSHRSMN1; SMN2TTRMMP1 | |
| SCHEMBL4202392 | 0.87 | MYC (0.47) | MYCTSHRSMN1; SMN2TTRMMP1 | |
| SCHEMBL11378079 | 0.85 | MGLL (0.41) | MYCTSHRSMN1; SMN2TTRFABP4 | |
| SCHEMBL587388 | 0.83 | GAA (0.41) | MMP1MMP2MMP3MMP9MMP12 | |
| SCHEMBL6252534 | 0.83 | MYC (0.44) | MYCTSHRSMN1; SMN2TTRMMP1 | |
| Hydrochloric Acid SCHEMBL28337695 | 0.82 | MYC (0.43) | MYCTSHRSMN1; SMN2TTRMMP1 | |
| SCHEMBL11341783 | 0.82 | MGLL (0.47) | MYCTSHRSMN1; SMN2TTRALDH1A1 | |
| SCHEMBL1807544 | 0.82 | MYC (0.43) | MYCTSHRSMN1; SMN2TTRMMP1 | |
| SCHEMBL1807545 | 0.82 | MYC (0.43) | MYCTSHRSMN1; SMN2TTRMMP1 | |
| SCHEMBL11254980 | 0.82 | ALDH1A1 (0.38) | TSHRMMP1MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109336895-B | Synthesis method of pholcodine | 宜昌人福药业有限责任公司 | 2020-05-26 | — | — | CN | disclosed |
| CN-109336895-A | A kind of synthetic method of pholcodine | 宜昌人福药业有限责任公司 | 2019-02-15 | — | — | CN | disclosed |
| US-20100267718-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | HIMMELSBACH FRANK | 2010-10-21 | — | — | US | disclosed |
| US-7196091-B2 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-27 | — | — | US | disclosed |
| US-20060264450-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | HIMMELSBACH FRANK | 2006-11-23 | — | — | US | disclosed |
| US-20050014772-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| US-4778932-A | Process for preparing diarylsulfones | NEW JAPAN CHEMICAL CO., LTD. (JP) | 1988-10-18 | — | — | US | disclosed |
| US-4518597-A | THROMBOSIS, ARTERIOSCLEROSIS, ANTITUMOR, ANTICOAGULANTS | DR. KARL THOMAE GMBH (DE) | 1985-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014772-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | RET, CYP11B1, CYP11B2 | MYC 536/4885TSHR 1105/4885SMN1; SMN2 4271/4885 |
| US-20060264450-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | RET, CYP11B1, CYP11B2 | MYC 536/4885TSHR 1105/4885SMN1; SMN2 4271/4885 |
| US-20100267718-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | RET, CYP11B1, CYP11B2 | MYC 536/4885TSHR 1105/4885SMN1; SMN2 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.